Q-Line Biotech, a twelve-year-old manufacturer of diagnostic reagents, steps into India's public markets at a moment when its own financial story is still being written. The company's IPO on the NSE SME Emerge platform raises Rs. 214.48 crore at a price that looks reasonable against its best recent earnings — yet considerably stretched against a more troubled fiscal year just behind it. In the long human endeavor of turning scientific capability into durable enterprise value, the question here is not whether the business is real, but whether its finest hour was a glimpse of the future or a for